Cholinergic Degeneration and Cognitive Function in Early GBA1-Related Parkinson's Disease
Sofie Slingerland1, Sygrid van der Zee1,2, Giulia Carli3,4
1Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Objective:
The phenotype of patients with Parkinson's disease carrying GBA1 variants (GBA-PD) suggest similarities to symptomatology associated with early cholinergic system degeneration. Therefore, this study aims to investigate the clinical features and the cholinergic innervation pattern in patients with early GBA-PD versus those without the GBA1 mutation (non-GBA-PD).
Methods:
A total of 46 GBA-PD and 104 non-GBA-PD subjects were included. Clinical assessments included motor and non-motor evaluation, as well as a comprehensive neuropsychological examination. Cholinergic system integrity was assessed using 1 8F-Fluoroethoxybenzovesamicol (18F-FEOBV) positron emission tomography (PET) to investigate the differences between GBA-PD and non-GBA-PD. Given the higher prevalence of females in GBA-PD, analyses were repeated when stratified by sex. Additionally, we examined the association between cognitive domains and whole-brain cholinergic binding in both groups. Exploratory analyses examined clinical and 18F-FEOBV binding differences among GBA1 variants.
Results:
GBA-PD patients exhibited a higher burden of non-motor symptoms and lower cognitive performance on executive functions and attention. We observed a more pronounced cholinergic denervation in GBA-PD, compared to non-GBA-PD, primarily in the anterior, central, and limbic regions. However, the distribution of cholinergic loss and its association with attention and executive dysfunction was comparable between GBA-PD and non-GBA-PD. In addition, the clinical presentation and cholinergic binding differed significantly between sexes.
Interpretation:
These results suggest an important role of early cholinergic denervation in GBA-PD patients, which is related to more severe cognitive dysfunction. ANN NEUROL 2025;98:398-409.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Neural Regulation


